IPO News
Prev Next
As on Jun 23, 2017 12:00 AM Your results on : IPO News    
GTPL Hathway subscribed 1.50 times
23-Jun-2017 (17:40)
GTPL Hathway subscribed 41% on day 2
22-Jun-2017 (16:55)
CDSL IPO subscribed over 170 times
22-Jun-2017 (14:02)
GTPL Hathway subscribed 27% on day 1
21-Jun-2017 (17:27)
CDSL IPO subscribed over 169 times
21-Jun-2017 (17:12)
Eris Lifesciences IPO subscribed 3.29 times
21-Jun-2017 (10:01)
CDSL IPO subscribed 6.85 times on day two
20-Jun-2017 (16:50)
Eris Lifesciences IPO Subscribed 3.25 times
20-Jun-2017 (16:46)

Eris Lifesciences' initial public offering (IPO) received bids for 5.17 crore shares compared with 1.59 crore shares on offer on the third and final day of the bidding for the IPO, data on NSE showed as at 16:30 IST. The IPO was subscribed 3.25 times.

The price band of the IPO has been fixed at Rs 600 to Rs 603 per share of face value of Re 1 each. The IPO opened for subscription on 16 June 2017 and closes today, 20 June 2017.

The offer comprises offer for sale of 2.89 crore shares. At the lower price band of Rs 600 per share, the issue size works out to Rs 1732.50 crore. At the higher price band of Rs 603, the issue size works out to Rs 1741.16 crore.

The offer for sale of 2.89 crore shares is by the selling shareholders comprising the promoters and promoters group Amit Bakshi, Himanshu Shah, Inderjeet Negi, Kaushal Shah, Rajendrakumar Patel, Bhikabhai Shah and Hetal Shah and private equity (PE) investor ChrysCapital. The PE transaction of ChrysCapital in August 2011 was a secondary sale by the promoters. ChrysCapital, exiting through the offer for sale, held 16.25% stake prior to the offer at Rs 87 per share. A discount of Rs 60 per share is being offered to eligible employees.

The objects of the issue are to get the benefits of listing the equity shares on the BSE and the NSE, to enhance visibility and brand image and provide liquidity to the existing shareholders.

Ahead of the bidding, IPO committee of the board of directors allocated 1.29 crore shares to 37 anchor investors at the higher end of the IPO price band at Rs 603 per share aggregating Rs 779.45 crore.

Eris Lifesciences' consolidated net profit rose 81.25% to Rs 242.08 crore on 21.43% rise in net sales to Rs 724.98 crore in the year ended 31 March 2017 (FY 2017) over FY 2016.

Incorporated in 2007, Gujarat-based Eris Lifesciences undertakes research and development (R&D) and manufactures and sells branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the Indian pharmaceutical market (IPM). The categories include cardiovascular, anti-diabetics, vitamins, gastroenterology and anti-infectives. The focus is on developing products in the chronic and acute categories that are linked to lifestyle-related disorders.

Eris Lifesciences IPO subscribed 75% on day two
19-Jun-2017 (17:21)
CDSL IPO subscribed 1.99 times on day 1
19-Jun-2017 (17:13)
CDSL raises Rs 154.06 crore from anchor investors
19-Jun-2017 (10:57)
Tejas Networks IPO subscribed 1.88 times
19-Jun-2017 (10:29)
Eris Lifesciences IPO subscribed 11% on day one
16-Jun-2017 (16:59)
Tejas Networks IPO subscribed 1.84 times
16-Jun-2017 (16:51)
Connect with us :   
About us
Our Services
Core Values
Investor Relations
Product & Services
Institutional Broking
Clearing Services
Trade & Products
Globe Connect Pro
Globe Trade Smart
Globe Connect Mobile/Tablet
Globe News Connect
Globe e-KYC Application
Back Office
Back Office
KYC/KDC Status
Mutual Fund
RMS Policy
Download Forms
Useful Links
Exchange Holidays
Policies, Procedures, Rights, Obligations and RDD
Guidance Note on FATCA and CRS May 2016
Right and Obligation, RDD, Guidance Note in Vernacular Language
In case of any grievances pleae write to / (For Trading) (For DP) (For PMS) (For Commodities)
SEBI Regn. No. NSE.:INB/INF/INE 230663732, TM No.:06637, Clearing No.- M50302 | SEBI Regn. No. BSE.:INB/INF/INE 010663731, Clearing No.- 3179 | SEBI Regn No. MSEI :INB/F 260663738, INE 260663732, TM Code-1004, Clearing Member Code- 4 | USE SEBI Regn no. - INE 270663732 , CM code: 06637 | SEBI Regn for DP : IN-DP-NSDL-97-99, NSDL- DP ID: IN300966, CDSL DP ID: 12020600 | Research Analysts Regn No. INH100001187 | PMS Regn No. INP000002361
* Through subsidiary Globe Commodities Ltd. --> Commodity Membership No.: NCDEX- FMC Regn. No. NCDEX/TCM/CORP/0004, TM Code-00012 | MCX- FMC Regn. No. MCX/TCM/CORP/0628, CM Code-8550 | ICEX- FMC Regn. No. ICEX/TCM/CORP/0011, TM Code- 1009 | NMCE- FMC Regn. No. NMCE/TCM/CORP/0018, TM Code-CL0111 | ACE - FMC Registration no.- ACEL/TCM/CORP/0163, TM code- 4001 | UCX FMC Regn. No.: UCX/TCM?CORP/0014, TM Code- 10014 | NCDEX Spot Exchange Membership no.- NCDEXSPOT-CR-07-10011
** Through step in subsidiary Globe Comex International DMCC --> DGCX **TM Id.1064, CM Id.3064*
"We also do Pro-Account trading in Commodity Segment.."
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Attention Investors:
"Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your Stock Brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors"
"Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors."
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
© 2013 Globe Capital Market Limited. All rights reserved
Designed, Developed and Content powered by C-MOTS Infotech (ISO 9001:2008 Certified) Privacy Policy Disclaimer Terms and Conditions